As director of the Pancreatic Cancer Center, Diane M. Simeone, MD leads a premier clinical team of experts who seek to provide compassionate, state-of-the-art care for patients who have pancreatic tumors and individuals at higher risk for the disease. Simeone also leads clinical trials and studies the molecular processes in pancreatic cancer development, working toward identifying ways to detect cancer early and creating new therapies to improve survival. As associate director of translational research at Perlmutter Cancer Center, Simeone strives to bring what scientists learn in the lab directly to the bedside to help manage all types of cancer. The past decades have seen several advances in cancer biology and genomics, and Simeone believes that there is a tremendous opportunity—and an obligation—to channel this progress to impact patients. Simeone has published more than 170 studies in leading peer-reviewed journals and currently serves as the chair of the scientific and medical advisory board of the Pancreatic Cancer Action Network and a member of the scientific advisory board for Let’s Win (Sharing Science Solutions for Pancreatic Cancer). Simeone has previously served as the president of the Society of University Surgeons and the American Pancreatic Association. As a member of the Institute of Medicine of the National Academy of Sciences and the National Cancer Institute’s Pancreatic Cancer Task Force Simeone currently serves as the principal investigator and lead of Precision Promise, an exciting new national clinical trials consortium focused on next-generation clinical trials for people who have pancreatic cancer.